Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in chronic myeloid leukemia
- Trial result
Chronic myeloid leukemia
Asciminib (STAMP inhibitor; BCR::ABL1 myristoyl-pocket) beats flumatinib in 1L CML-CP on EMR/MMR and AE discontinuations (China MAIC)
Asciminib is a first-in-class STAMP BCR::ABL1 inhibitor (myristoyl-pocket binder), indirectly compared vs flumatinib (an ATP-competitive 2G TKI used mainly in China) using an anchored matching-adjusted indirect…
NCT04971226 - Trial result
Chronic myeloid leukemia
Asciminib (BCR::ABL1 STAMP inhibitor) delivers durable molecular responses in T315I-mutant CML
Asciminib, an allosteric inhibitor that targets the ABL1 myristoyl pocket rather than the ATP-binding site, was evaluated at 200 mg twice daily in a nonrandomized Phase 1 trial (NCT02081378) of heavily pretreated…
NCT02081378 - Trial result Spotlight
Chronic myeloid leukemia
Asciminib deepens frontline molecular responses in East Asian CML-CP subgroup
Asciminib is a first-in-class allosteric BCR–ABL1 inhibitor that binds the ABL myristoyl pocket rather than the ATP-binding site targeted by standard TKIs. In the East Asian subgroup of the Phase 3 ASC4FIRST trial in…
NCT04971226 - Trial result
Chronic myeloid leukemia
Asciminib (ABL myristoyl-pocket “STAMP” inhibitor) sustains deeper molecular responses vs frontline ATP-competitive TKIs in ASC4FIRST (wk 144)
Asciminib (ASC) is a first-in-class allosteric BCR::ABL1 inhibitor that binds the ABL myristoyl pocket (vs ATP-site TKIs like imatinib/dasatinib/nilotinib/bosutinib). In the multicenter open-label Phase 3 ASC4FIRST…
NCT04971226 - Trial result
Chronic myeloid leukemia
Asciminib (STAMP inhibitor; ABL myristoyl-pocket) delivers rapid MR2/MR3 with low discontinuation in 1L US CML-CP RWE
Asciminib (SCEMBLIX) is a first-in-class BCR::ABL1 “STAMP” inhibitor that binds the ABL myristoyl pocket (allosteric), here used as first-line therapy for newly diagnosed Ph+ CML-CP (no T315I) in a US retrospective…
- New trial
Chronic myeloid leukemia
Phase 1/2 asciminib STAMP BCR-ABL1 inhibitor with FLAG-Ida + venetoclax BCL-2 inhibitor
MD Anderson is running this Phase 1b/2 study to define safety (Phase 1b) and estimate efficacy (Phase 2) of adding asciminib (Novartis; a STAMP inhibitor that targets the ABL myristoyl pocket on BCR-ABL1) to…
NCT07604233 Exploratory - Trial result
Chronic myeloid leukemia
Asciminib (STAMP/ABL myristoyl-pocket inhibitor) posts ~39% Week-48 MMR in ≥3L CML-CP optimization study
Asciminib (Scemblix) is a first-in-class STAMP inhibitor that allosterically targets the ABL1 myristoyl pocket (vs ATP-competitive TKIs), evaluated in the non-comparative Phase 3b ASC4OPT study (NCT04948333) in…
NCT04948333
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.